Assay News and Research

RSS
HPV16 ctDNA assay predicts treatment response in metastatic head and neck cancer

HPV16 ctDNA assay predicts treatment response in metastatic head and neck cancer

Study explains how SARS-CoV-2 variants differ in binding to ACE2 receptor

Study explains how SARS-CoV-2 variants differ in binding to ACE2 receptor

New integrative NGS panel for analysis of standard and novel biomarkers in lymphoid neoplasms

New integrative NGS panel for analysis of standard and novel biomarkers in lymphoid neoplasms

Spike-containing virus-like particles induce robust sterilizing immunity against SARS-CoV-2 in macaques

Spike-containing virus-like particles induce robust sterilizing immunity against SARS-CoV-2 in macaques

SARS-CoV-2 variants of concern employ different strategies of antibody escape

SARS-CoV-2 variants of concern employ different strategies of antibody escape

Immunity to SARS-CoV-2 in renal transplant and dialysis patients using Pfizer/BioNTech and Moderna vaccines

Immunity to SARS-CoV-2 in renal transplant and dialysis patients using Pfizer/BioNTech and Moderna vaccines

Impaired immune response to SARS-CoV-2 mRNA vaccination in immunocompromised patients

Impaired immune response to SARS-CoV-2 mRNA vaccination in immunocompromised patients

Higher temperatures could limit the spread of dengue infection

Higher temperatures could limit the spread of dengue infection

Genomic test may help identify prostate cancer patients at high risk of disease progression

Genomic test may help identify prostate cancer patients at high risk of disease progression

Monoclonal antibody CT-P59 demonstrates potent antiviral efficacy against SARS-CoV-2 delta variant

Monoclonal antibody CT-P59 demonstrates potent antiviral efficacy against SARS-CoV-2 delta variant

Budesonide’s antiviral effect against SARS-CoV-2

Budesonide’s antiviral effect against SARS-CoV-2

A novel interferon-γ release assay for detection of SARS-CoV-2 specific T-cell response

A novel interferon-γ release assay for detection of SARS-CoV-2 specific T-cell response

5.6% seroprevalence of SARS-CoV-2 antibodies in England during second wave

5.6% seroprevalence of SARS-CoV-2 antibodies in England during second wave

Researchers discover camelid-derived two nanobodies that target SARS-CoV-2

Researchers discover camelid-derived two nanobodies that target SARS-CoV-2

Clinical trials during a pandemic – lessons from COVID-19

Clinical trials during a pandemic – lessons from COVID-19

Researchers identify an unexpected effect for already characterized active substances

Researchers identify an unexpected effect for already characterized active substances

SARS-COV-2 infection leads to neutralizing and protective serological responses in over 70% of DPs

SARS-COV-2 infection leads to neutralizing and protective serological responses in over 70% of DPs

Efficacy of mRNA vaccine-induced memory B cells against SARS-CoV-2 variants

Efficacy of mRNA vaccine-induced memory B cells against SARS-CoV-2 variants

Virginia Tech's in-house development of novel SARS-CoV-2 test shows the power of academic labs

Virginia Tech's in-house development of novel SARS-CoV-2 test shows the power of academic labs

New study disproves suspicion that dengue raises risk of zika-related microcephaly

New study disproves suspicion that dengue raises risk of zika-related microcephaly

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.